" class="no-js "lang="en-US"> ADA Names Charles D. Henderson as New Chief Executive Officer - Medtech Alert
Thursday, June 13, 2024

ADA Names Charles D. Henderson as New Chief Executive Officer

The American Diabetes Association® (ADA), the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic, is proud to announce Charles D. “Chuck” Henderson as the new Chief Executive Officer (CEO). Following six months of serving in the interim office of the CEO, Charles was selected from a pool of highly qualified candidates to serve in this position in a search lead by the Furst Group, which is ranked as a Top 10 executive search firm by Modern Healthcare and one of “America’s Best Executive Search Firms” by Forbes.

Charles joined the ADA in January 2020 from Champion Life Safety Solutions where he was CEO & President. Prior to that, he was a Senior Executive running multi-billion territories across the country for Dell Healthcare, Viacom(MTV Networks), and business development for Commonground Marketing (including executing special events in the field), and RAPP. His professional skillset and success, coupled with his passion and desire to give back makes this a perfect time for him to lead a top non-profit organization. After spending over 24 years in for-profit sectors and volunteering in the non-profit sector, Charles is passionate about spending the balance of his career in a space that will make a significant impact on millions of lives. Philanthropy and Sales/Fundraising is thread through the fabric of his DNA.

“I am confident that Charles will continue to catapult the ADA into the future with innovative practices, servant leadership, and draw upon his successes as the interim CEO,” said Chris Ralston, ADA National Board Chairman, “to ensure that the mission of the ADA continues and the 37 million people living with diabetes and their loved ones feel supported, heard and seen until we find a cure.”

During his time at the ADA as interim CEO, Charles was responsible for securing over $18 million in donations and sponsorship. There has been an increase in staff. Major partnerships were formed and renewed. While various initiatives were created to help people living with diabetes, which included a new co-pay relief fund. All of which shows how Charles will continue to lead the ADA into the future.

“I am very excited that Chuck has been elevated to the role of the Chief Executive Officer for ADA,” said Charlotte Carter, Chief Financial Officer for the ADA. “I believe he has the skillset and background that ADA needs to help us accelerate as an organization as we strive to help people living with or are impacted by diabetes. I look forward to partnering with and supporting Chuck in his new role.”

“We are so excited to have our new CEO lead the American Diabetes Association to greater heights and impact for all people affected by diabetes,” said Dr. Robert Gabbay, Chief Science and Medical Officer for the ADA.

A native Texan, Chuck has a strong commitment to his family, community, and church. An avid golfer, Chuck is also involved with his Alma mater, Texas A&M, where he serves on boards and leverages his professional skills to raise money for the school in different capacities. He was also a 3 year starter, letterman, and co-captain of the Texas A&M Men’s basketball team. Charles is married to his beautiful wife Courtney, and they have a lovely daughter, Charlie who is 14-years old.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more